XBIO
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Ref P/E N/A, P/B 0.97
- P/B ratio of 0.97 suggests the stock is not overvalued relative to assets
- No P/E or Graham Number due to lack of earnings
Ref Growth rates
- Revenue growth of 18.10%
- Improving EPS trajectory (YoY +67.6%)
- Earnings remain deeply negative
Ref Historical trends
- Recent 1Y return of +22.8%
- 5Y change of -84.6% indicates long-term value destruction
Ref Piotroski F-Score
- No debt
- High current ratio
- Piotroski F-Score 1/9 indicates failing fundamental health
Ref Yield N/A
- No dividend payments
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for XBIO and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
XBIO
Xenetic Biosciences, Inc.
Primary
|
-84.6% | -28.5% | +22.8% | -18.9% | +4.7% | -12.1% |
|
LUCY
Lucyd, Inc
Peer
|
-99.1% | -98.6% | -48.1% | -41.2% | -1.8% | +1.9% |
|
ITOC
iTonic Holdings Ltd.
Peer
|
-92.6% | -92.6% | -90.8% | -60.0% | -17.4% | -8.2% |
|
MGRX
Mangoceuticals, Inc.
Peer
|
-99.3% | -97.5% | -78.4% | -84.5% | +2.4% | +2.4% |
|
BMRA
Biomerica, Inc.
Peer
|
-95.7% | -88.5% | -46.5% | -34.3% | -3.0% | 0.0% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
XBIO
Xenetic Biosciences, Inc.
|
BEARISH | $7.17M | - | -40.0% | -90.1% | $3.13 | |
|
LUCY
Lucyd, Inc
|
BEARISH | $6.93M | - | -83.6% | -285.2% | $1.1 | Compare |
|
ITOC
iTonic Holdings Ltd.
|
BEARISH | $6.92M | - | -71.2% | -% | $0.28 | Compare |
|
MGRX
Mangoceuticals, Inc.
|
BEARISH | $6.67M | - | -141.7% | -% | $0.39 | Compare |
|
BMRA
Biomerica, Inc.
|
BEARISH | $7.76M | - | -84.3% | -90.3% | $2.57 | Compare |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
XBIO's 10-K filing for the period ending December 2025 does not provide specific financial highlights in the provided excerpts. However, the company identifies geopolitical instability, specifically conflicts in Ukraine and the Middle East and related sanctions, as significant risks to its future results and financial position.
As of September 30, 2025, Xenetic Biosciences, Inc. reported a decrease in cash and equivalents to $4.12 million from $6.17 million at year-end 2024, with total assets declining to $5.07 million. Total liabilities increased to $1.11 million, driven primarily by a rise in accounts payable. These trends indicate a tightening liquidity position and increasing short-term obligations.
Xenetic Biosciences, Inc. reported a decrease in cash and equivalents to $4.78 million as of June 30, 2025, down from $6.17 million at year-end 2024. Total assets declined to $5.35 million, while total liabilities remained relatively stable at $903,430. The primary financial risk is the reduction in liquidity and the associated cash burn required to sustain operations.
Past News Coverage
Recent headlines mentioning XBIO from our newsroom.